Patent intelligence · US
US 11008289
Crystalline freebase forms of a biphenyl compound
Crystalline freebase forms of a biphenyl compound
Patent details — US 11008289
- Jurisdiction
- US
- Status
- granted
- Grant date
- May 18, 2021
- Expiration
- May 13, 2041
- Applicant
- Theravance Biopharma R&D IP, LLC
- Claims
- 9
- CPC classes
- A61K, A61K31/4545, A61K45/06, A61K9/124
Quick answer
US 11008289 (Crystalline freebase forms of a biphenyl compound) is held by Theravance Biopharma R&D IP, LLC. Status: granted. Granted May 18, 2021. Expires May 13, 2041 (15 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Theravance Biopharma R&D IP, LLC
- Grant date
- Expiration
- Claims
- 9
- CPC classes
- A61K, A61K31/4545, A61K45/06, A61K9/124, A61K9/1623, A61P
More from Theravance Biopharma R&D IP, LLC
Related pharmaceutical patents in our USPTO index.
-
US 12384761
Imidazolo indazole compounds as JAK inhibitors
granted -
US 12358931
3-((1R,3s,5S)-3-((7-((5-methyl-1H-pyrazol-3-yl)amino)-1,6-naphthyridin-5-yl)amino)-8-azabicyclo[3.2.1]octan-8-yl) propanenitrile as a JAK kinase inhibitor
granted -
US 12351561
Crystalline (2S,4R)-5-(5'-chloro-2'-fluoro-[1,1'-biphenyl]-4-yl)-2-(ethoxymethyl)-4-(3-hydroxyisoxazole-5-carboxamido)-2-methylpentanoic acid and uses thereof
granted -
US 12285417
Methods for treating chronic obstructive pulmonary disease
granted -
US 12258316
Biphenyl compounds useful as muscarinic receptor antagonists
granted -
US 12239638
Crystalline form of a 4-[2-(2-fluorophenoxymethyl)phenyl]piperidine compound
granted -
US 12172994
Pyrimidine compound as JAK kinase inhibitor
granted -
US 12122773
Crystalline hydrate of a JAK inhibitor compound
granted
Frequently asked questions
What is US patent 11008289?
US 11008289 (Crystalline freebase forms of a biphenyl compound) is held by Theravance Biopharma R&D IP, LLC. Status: granted. Granted May 18, 2021. Expires May 13, 2041 (15 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11008289?
Theravance Biopharma R&D IP, LLC is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 635 pharmaceutical patents for this assignee.
When does US 11008289 expire?
Our index shows an expiration date of May 13, 2041 (15 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.